NASDAQ · MMSI

Merit Medical Systems Inc.

$76.10 +$1.78 (+2.40%) 1D After hours

Key Metrics

$4.43B
Market cap
31.82×
P/E · TTM
$1.54B
Revenue · TTM
$139.34M
Net income
EPS · TTM $2.27
Dividend yield
Free cash flow $220.82M
Beta · 1Y 0.48
EBITDA · TTM $310.90M
Gross margin 48.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 11
    From its Feb 18 high, the share price fell 27%.

    Peak close $82.98 on Feb 18; trough close $60.31 on May 11. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -27%
  • May 1
    The stock moved -9.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 1

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.43B
Enterprise value$4.68B
Shares outstanding59.7M
52-wk range$59.74 – $94.75
Avg volume · 20D442.3K
Net cash −$247.08M
Book value / share$26.55
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Merit Medical Systems Inc.
IPO dateMay 10, 1990
Employees7500

Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E31.82
P/S2.87
P/FCF20.08
EV/EBITDA15.06
EV/Sales3.03
Graham №$36.85

Profitability

Gross 48.7%
Operating 12.1%
Net 9.0%
FCF 14.3%
ROE / ROIC 8.6% · 7.4%

Financial Health

Current ratio5.08
Quick ratio3.46
Debt / equity0.45
Debt / EBITDA 2.36
Net cash −$247.08M
Working capital$884.90M

Cash Flow · TTM

Operating CF $297.48M
Capex −$76.66M
Free cash flow $220.82M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

4.1
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$36.85 vs $76.10
Trades 2.1× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings